안전 펜니들 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of safety pen needles Market

The global safety pen needles market was valued at USD 768.02 million in 2025 and is projected to grow from USD 818.52 million in 2026 to USD 1,493.31 million by 2034, registering a CAGR of 7.81% during the forecast period. North America dominated the market with a 42.34% share in 2025, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong presence of leading manufacturers.

Safety pen needles are sterile, single-use needles used with insulin pens, equipped with protective features such as needle shields or auto-retraction systems to prevent accidental needlestick injuries. These devices enhance safety for both patients and caregivers and are increasingly preferred over conventional syringes and standard pen needles.

Market Dynamics

Market Drivers

Rising Prevalence of Diabetes

The growing global burden of diabetes is a primary growth driver. According to the IDF Diabetes Atlas (2025), approximately 11.1% of the adult population aged 20-79 years is living with diabetes. Rapid urbanization, sedentary lifestyles, and rising obesity rates are significantly contributing to increased insulin dependency. As insulin therapy requires frequent injections, the demand for safer and more convenient injection devices such as safety pen needles is rising steadily.

Furthermore, increased awareness programs in developed nations promoting safe injection practices are supporting higher product adoption.

Market Restraints

Emergence of Alternative Drug Delivery Systems

The development of needle-free and alternative drug delivery technologies may limit market growth. In November 2024, Sol-Millennium launched the Insujet needle-free insulin delivery device in the U.S. Such advancements provide patients with less invasive options, potentially reducing reliance on safety pen needles.

Market Opportunities

Shift Toward Home Healthcare

The increasing preference for home-based diabetes management presents significant growth opportunities. Around 60% of global insulin users utilize insulin pens, as reported by NCBI (September 2023). Safety pen needles, with features such as passive shielding and auto-disable mechanisms, reduce injury risk and cross-contamination, making them suitable for elderly patients and caregivers. Expanding remote patient monitoring and personalized healthcare models are further strengthening demand, particularly in emerging markets across Asia Pacific and Latin America.

Market Challenges

High Cost of Safety Pen Needles

Safety pen needles are significantly more expensive than standard pen needles. In June 2025, the NHS highlighted that safety needles can be up to eight times more expensive than conventional needles, limiting prescriptions in cost-sensitive healthcare systems. Lack of reimbursement policies in developing nations such as India and China may further restrict adoption.

Market Trends

Integration of Ultra-Thin Needle Technology

Manufacturers are integrating ultra-thin needle designs (as small as 4 mm and 32-34 gauge) with advanced safety mechanisms. These innovations reduce injection pain and anxiety, enhancing therapy adherence among insulin-dependent patients. Co-development with pharmaceutical companies for GLP-1 agonists and insulin pens is further driving technological advancements.

Segmentation Analysis

By Product Type

The active safety pen needles segment dominated in 2024, driven by ease of use and reliable dose delivery. Studies have demonstrated high satisfaction levels among healthcare professionals. Passive safety pen needles also hold a substantial share due to automatic shielding features that eliminate manual activation.

By Drug Type

The insulin segment dominated in 2024, supported by rising diabetes prevalence and frequent product launches. For example, in January 2025, Novo Nordisk launched Awiqli (insulin icodec) in Japan. The GLP-1 segment held the second-largest share, fueled by increasing prescriptions for type 2 diabetes and obesity management.

By Disease Indication

The diabetes segment dominated in 2024, owing to continuous innovation in safety pen needles and increasing home-based insulin therapy. The obesity segment accounted for the second-largest share due to its link with type 2 diabetes.

By Needle Size

The 4 mm segment dominated in 2024, attributed to fewer side effects and reduced risk of intramuscular injections. Clinical data supports its safety even among obese individuals.

By Distribution Channel

The retail pharmacy segment dominated in 2024, supported by global expansion of pharmacy chains. For instance, in March 2025, CVS Pharmacy announced plans to open new stores across the U.S. Online pharmacies are expected to register the highest CAGR due to convenience and home delivery benefits.

Regional Insights

In 2025, North America generated USD 325.22 million, maintaining its leading position. Growth is supported by regulatory approvals, product launches, and high diabetes incidence.

Europe held the second-largest share in 2024, driven by rising diabetes prescriptions. The NHS reported 71 million diabetes-related prescriptions in 2024 in the U.K.

Asia Pacific is projected to register the highest CAGR through 2034, owing to high diabetes prevalence and increasing distribution partnerships. Latin America and the Middle East & Africa are expected to witness steady growth supported by rising obesity rates and improved healthcare access.

Competitive Landscape

Key players include Embecta Corp., Cardinal Health, MTD Medical Technology and Devices, UltiMed, Inc., Allison Medical, Owen Mumford, VMG, and Neon Diagnostics Limited. Companies are focusing on acquisitions, partnerships, and capacity expansions. Notably, in November 2024, Cardinal Health announced its acquisition of Advanced Diabetes Supply Group for USD 1.1 billion.

Conclusion

The global safety pen needles market is set for robust growth from USD 768.02 million in 2025 to USD 818.52 million in 2026, reaching USD 1,493.31 million by 2034 at a CAGR of 7.81%. Rising diabetes prevalence, increasing preference for home healthcare, and technological innovations in ultra-thin safety needles are key growth drivers. Although high product costs and emerging needle-free alternatives pose challenges, expanding healthcare awareness and strategic initiatives by major industry players are expected to sustain long-term market expansion through 2034.

Segmentation By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Region

By Product Type * Active Safety Pen Needles

• Passive Safety Pen Needles

By Drug Type * Insulin

• GLP-1
• Growth Hormone
• Others

By Disease Indication * Diabetes

• Obesity
• Hormone Deficiency
• Others

By Needle Size * 4 mm

• 5 mm
• 6 mm
• 8 mm
• 12 mm

By Distribution Channel * Hospital Pharmacy

• Retail Pharmacy
• Online Pharmacy

By Region * North America (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)

• U.S.
• Canada
• Europe (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Diabetes - by Key Countries/Regions, 2025
• 4.2. Prevalence of Obesity - by Key Countries/Regions, 2021-2034
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)

5. Global Safety Pen Needles Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Active Safety Pen Needles
  • 5.1.2. Passive Safety Pen Needles
• 5.2. Market Analysis, Insights and Forecast - By Drug Type
  • 5.2.1. Insulin
  • 5.2.2. GLP-1
  • 5.2.3. Growth Hormone
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Diabetes
  • 5.3.2. Obesity
  • 5.3.3. Hormone Deficiency
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Drug Type
  • 5.4.1. 4 mm
  • 5.4.2. 5 mm
  • 5.4.3. 6 mm
  • 5.4.4. 8 mm
  • 5.4.5. 12 mm
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacy
  • 5.5.2. Retail Pharmacy
  • 5.5.3. Online Pharmacy
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Safety Pen Needles Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Active Safety Pen Needles
  • 6.1.2. Passive Safety Pen Needles
• 6.2. Market Analysis, Insights and Forecast - By Drug Type
  • 6.2.1. Insulin
  • 6.2.2. GLP-1
  • 6.2.3. Growth Hormone
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. Diabetes
  • 6.3.2. Obesity
  • 6.3.3. Hormone Deficiency
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Drug Type
  • 6.4.1. 4 mm
  • 6.4.2. 5 mm
  • 6.4.3. 6 mm
  • 6.4.4. 8 mm
  • 6.4.5. 12 mm
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacy
  • 6.5.2. Retail Pharmacy
  • 6.5.3. Online Pharmacy
• 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Safety Pen Needles Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Active Safety Pen Needles
  • 7.1.2. Passive Safety Pen Needles
• 7.2. Market Analysis, Insights and Forecast - By Drug Type
  • 7.2.1. Insulin
  • 7.2.2. GLP-1
  • 7.2.3. Growth Hormone
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. Diabetes
  • 7.3.2. Obesity
  • 7.3.3. Hormone Deficiency
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Drug Type
  • 7.4.1. 4 mm
  • 7.4.2. 5 mm
  • 7.4.3. 6 mm
  • 7.4.4. 8 mm
  • 7.4.5. 12 mm
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacy
  • 7.5.2. Retail Pharmacy
  • 7.5.3. Online Pharmacy
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia pacific Safety Pen Needles Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Active Safety Pen Needles
  • 8.1.2. Passive Safety Pen Needles
• 8.2. Market Analysis, Insights and Forecast - By Drug Type
  • 8.2.1. Insulin
  • 8.2.2. GLP-1
  • 8.2.3. Growth Hormone
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. Diabetes
  • 8.3.2. Obesity
  • 8.3.3. Hormone Deficiency
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Drug Type
  • 8.4.1. 4 mm
  • 8.4.2. 5 mm
  • 8.4.3. 6 mm
  • 8.4.4. 8 mm
  • 8.4.5. 12 mm
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacy
  • 8.5.2. Retail Pharmacy
  • 8.5.3. Online Pharmacy
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Safety Pen Needles Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Active Safety Pen Needles
  • 9.1.2. Passive Safety Pen Needles
• 9.2. Market Analysis, Insights and Forecast - By Drug Type
  • 9.2.1. Insulin
  • 9.2.2. GLP-1
  • 9.2.3. Growth Hormone
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. Diabetes
  • 9.3.2. Obesity
  • 9.3.3. Hormone Deficiency
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Drug Type
  • 9.4.1. 4 mm
  • 9.4.2. 5 mm
  • 9.4.3. 6 mm
  • 9.4.4. 8 mm
  • 9.4.5. 12 mm
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacy
  • 9.5.2. Retail Pharmacy
  • 9.5.3. Online Pharmacy
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Safety Pen Needles Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Active Safety Pen Needles
  • 10.1.2. Passive Safety Pen Needles
• 10.2. Market Analysis, Insights and Forecast - By Drug Type
  • 10.2.1. Insulin
  • 10.2.2. GLP-1
  • 10.2.3. Growth Hormone
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.3.1. Diabetes
  • 10.3.2. Obesity
  • 10.3.3. Hormone Deficiency
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Drug Type
  • 10.4.1. 4 mm
  • 10.4.2. 5 mm
  • 10.4.3. 6 mm
  • 10.4.4. 8 mm
  • 10.4.5. 12 mm
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacy
  • 10.5.2. Retail Pharmacy
  • 10.5.3. Online Pharmacy
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. Embecta Corp.
  • 11.2.2. Cardinal Health
  • 11.2.3. MTD Medical Technology and Devices
  • 11.2.4. UltiMed, Inc
  • 11.2.5. Allison Medical, Inc.
  • 11.2.6. Owen Mumford
  • 11.2.7. Medline Industries, LP.
  • 11.2.8. VMG
  • 11.2.9. Neon Diagnostics Limited